Sarthak Gupta, M.D., conducts research to better understand sex differences in neutrophil biology. He is also an investigator on several ongoing clinical trials in systemic lupus erythematosus at the NIH.
This public-private partnership seeks to develop new ways of identifying and validating promising biological targets for diagnostics and drug development.
Led by Dr. Mariana Kaplan, the branch studies autoimmune diseases, like lupus and rheumatoid arthritis, seeking treatments and improved outcomes.
Dr. Kaplan’s research focuses on identifying the molecular mechanisms that promote the initiation and perpetuation of perturbed immune responses and the development of organ damage and premature vascular disease in systemic autoimmunity.
Dr. Lewandowski leads a team of scientists studying the genetics of early-onset systemic lupus erythematosus patients in populations around the globe. Her research focuses on genetic drivers of severe disease and inflammation in diverse cohorts worldwide.
What is epidermolysis bullosa? Epidermolysis bullosa is a group of rare diseases that cause fragile skin that leads to blisters and tearing. Tears, sores, and blisters in the skin happen when something rubs or bumps the skin. They can appear anywhere on the body. In severe cases, blisters may also develop inside the body. The symptoms of the disease usually begin at birth or during infancy and range from mild to severe.
What is systemic lupus erythematosus (lupus)? Systemic lupus erythematosus (lupus) is a chronic (long-lasting) autoimmune disease that can affect many parts of the body, including the: Skin. Joints. Heart. Lungs. Kidneys. Brain. Lupus happens when the immune system, which normally helps protect the body from infection and disease, attacks its own tissues. This attack causes inflammation and, in some cases, permanent tissue damage. If you have lupus, you may have times of illness (flares) and times of wellness (remission). Lupus flares can be mild to serious, and they do not follow a pattern. However, with treatment, many people with lupus
Research supported by the Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) provides new insights into tissue damage for these autoimmune conditions. Findings include the identification of novel molecular signatures related to immune system signaling in kidney cells that may reflect their active role in disease process; molecular targets, including specific white blood cells, for potential treatment in lupus nephritis; and specific types of fibroblasts and white blood cells that are involved in rheumatoid arthritis.
Scientists can distinguish between highly similar cell types using cutting-edge laboratory procedures. Using such techniques, IRP researchers have identified a particular variety of cell in a specific stage of its life cycle as a primary culprit behind the autoimmune disease known as lupus.
Researchers have identified a potential treatment to reduce the risk of cardiovascular disease in people with systemic lupus erythematosus (SLE), a chronic autoimmune disease.
Known as the “disease with a thousand faces,” systemic lupus erythematosus is a lifelong autoimmune disease with a wide range of symptoms and signs—fatigue, fever, joint pain, facial rash and skin lesions, shortness of breath, and more. It may develop suddenly or slowly and be mild or severe, with people affected going through periods of flare up and remission of their symptoms.